{
    "info": {
        "nct_id": "NCT05039281",
        "official_title": "Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination with Cabozantinib in Patients with Recurrent Glioblastoma (rGBM)",
        "inclusion_criteria": "* Signed informed consent form (ICF)\n* Ability and willingness to comply with the requirements of the study protocol\n* Age >= 18 years\n* Have histologically confirmed World Health Organization grade IV glioma (glioblastoma or gliosarcoma). Archival tissue will be required for diagnosis confirmation. Receipt of archival tissue is not required for the start of treatment\n* Patients must have been previously treated with radiation and temozolomide\n* Patients must be at least 12 weeks out from completion of concurrent chemoradiation\n* Have a performance status of >= 60 on the Karnofsky performance status (KPS)\n* Patients at either first or second recurrence will be considered eligible\n* A baseline brain magnetic resonance imaging (MRI) obtained no more than 14 days prior to study enrollment\n* Absolute neutrophil count (ANC) >= 1,500 /mcL\n* Platelets >= 100,000 /mcL\n* Hemoglobin >= 9 g/dL or >= 5.6 mmol/L\n* Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN\n\n  * Creatinine clearance should be calculated per institutional standard\n* Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol) OR 24 hour (h) urine protein =< 1g\n* Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN\n* Serum albumin >= 2.8 g/dl\n* International normalized ratio (INR) or prothrombin time (PT) activated partial thromboplastin time (aPTT) =< 1.3 X ULN\n* All screening labs should be performed within 14 days (+3 working days) of treatment initiation\n* Female subject of childbearing potential should have a negative serum pregnancy test within 14 days (+/- 3 working days) of study enrollment\n* Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the duration of the study and 5 months after the last dose of study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year\n* Male subjects should agree to use an adequate method of contraception during the course of the study and 5 months after the last dose of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel wafers will be excluded. Active treatment with the Optune device will be excluded\n* Has received radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment, or systemic treatment with radionuclides within 6 weeks before first dose of study treatment\n* Has clinically relevant ongoing complications from prior radiation therapy\n* Is currently participating in any other recurrent therapeutic trial after completion of chemoradiation\n* Has history of cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation\n* Any serious medical condition that interferes with adherence to study procedures\n* Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0)\n* Has known leptomeningeal disease, gliomatosis cerebri, extracranial disease, or multifocal disease. Subject has multifocal glioblastoma (GBM), defined as discrete sites of contrast enhancing disease without contiguous T2/fluid attenuated inversion recovery (FLAIR) abnormality that require distinct radiotherapy ports. Satellite lesions that are associated with a contiguous area of T2/FLAIR abnormality as the main lesion(s) and that are encompassed within the same radiotherapy port as the main lesion(s) are permitted\n* Has history of interstitial lung disease or active, non-infectious pneumonitis\n* Has an active infection requiring systemic therapy\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit\n* Contraindication for undergoing MRIs\n* Inability to comply with study and follow-up procedures\n* History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\n\n  * Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\n  * Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible\n  * Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n    * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\n    * Rash must cover less than 10% of body surface area (BSA)\n    * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)\n    * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)\n* Has a medical history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active pneumonitis\n\n  * History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications\n* History of human immunodeficiency virus (HIV) infection or active hepatitis B (HBV) (chronic or acute) or hepatitis C infection\n\n  * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible. Patients will be sampled for HBV DNA and will be referred to a virologist to monitor for HBV re-activation\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA\n* Active tuberculosis\n* Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1\n* Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\n\n  * Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible\n* Anticipation of need for a major surgical procedure (e.g., laparoscopic nephrectomy, gastrointestinal [GI] surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment, or of need for a minor surgery within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible\n* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study and for 5 months after last dose of atezolizumab\n* Patients may not receive concomitant chemotherapy, hormonal therapy, immunotherapy, or radiotherapy while patients are on study\n* MEDICATION-RELATED EXCLUSION CRITERIA:\n* Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment\n* Prior treatment with anti-angiogenic (e.g. anti-vascular endothelial growth factor [VEGF]) therapeutic antibody or pathway targeting agents\n* Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]- or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1\n* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\n\n  * Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\n  * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, fusion proteins or components of cabozantinib\n* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* Evidence of recent hemorrhage on post-operative MRI of the brain, however patients with clinically asymptomatic presence of hemosiderin, resolving post-operative changes and punctate intratumoral hemorrhage are permitted\n* Known lesions invading or encasing any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible\n* Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment\n\n  * Note: if a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 minutes after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility\n* Inability to swallow tablets\n* Inadequately controlled hypertension (defined as systolic blood pressure > 140mmHg and/or diastolic blood pressure > 90mmHg)\n* A history of or active nephrotic syndrome\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Assocation (NYHA) grade II or greater congestive heart failure\n* History of myocardial infarction or unstable angina within 6 months prior to study enrollment\n* History of stroke or transient ischemic attack (TIA) within 6 months prior to study enrollment\n* Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrollment\n* History of clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or any other history of significant bleeding (e.g. pulmonary hemorrhage) within 12 weeks before first dose of study treatment\n* Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)\n* Major surgical procedure, open biopsy, intracranial biopsy, ventriculoperitoneal shunt or significant traumatic injury within 28 days prior to study enrollment\n* Core biopsy (excluding intracranial biopsy) or other minor surgical procedure within 107 days prior to study enrollment. Placement of a central vascular access device if performed within 2 days prior to cabozantinib administration\n* History of abdominal fistula, bowel obstruction, gastrointestinal perforation or intra-abdominal abscess within 6 months before first dose of study treatment\n\n  * Note: complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment\n* History of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction\n* History of intracranial abscess within 6 months prior to study enrollment\n* Clinically-significant disorders that would preclude safe study participation\n\n  * Serious non-healing wound, active ulcer or untreated bone fracture\n  * Uncompensated/symptomatic hypothyroidism\n  * Moderate to severe hepatic impairment (Child-Pugh B or C)\n* Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g. , dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel)\n\n  * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH) are allowed\n  * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor are also allowed",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Creatinine clearance should be calculated per institutional standard",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance should be calculated per institutional standard",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "per institutional standard"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients at either first or second recurrence will be considered eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients at either first or second recurrence",
                    "criterion": "recurrence number",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "first",
                                "second"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subject of childbearing potential should have a negative serum pregnancy test within 14 days (+/- 3 working days) of study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Female subject of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "should have a negative serum pregnancy test",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days (+/- 3 working days) of study enrollment",
                    "criterion": "timing of serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "time window before enrollment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 17,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a performance status of >= 60 on the Karnofsky performance status (KPS)",
            "criterions": [
                {
                    "exact_snippets": "performance status of >= 60 on the Karnofsky performance status (KPS)",
                    "criterion": "Karnofsky performance status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1,500 /mcL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1,500 /mcL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male subjects should agree to use an adequate method of contraception during the course of the study and 5 months after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Male subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "should agree to use an adequate method of contraception during the course of the study and 5 months after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the course of the study",
                                "5 months after the last dose of study treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have histologically confirmed World Health Organization grade IV glioma (glioblastoma or gliosarcoma). Archival tissue will be required for diagnosis confirmation. Receipt of archival tissue is not required for the start of treatment",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed World Health Organization grade IV glioma (glioblastoma or gliosarcoma)",
                    "criterion": "glioma grade",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": "World Health Organization grade IV"
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "glioblastoma",
                                "gliosarcoma"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Archival tissue will be required for diagnosis confirmation",
                    "criterion": "archival tissue for diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin >= 2.8 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin >= 2.8 g/dl",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have been previously treated with radiation and temozolomide",
            "criterions": [
                {
                    "exact_snippets": "previously treated with radiation",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with ... temozolomide",
                    "criterion": "temozolomide",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dL or >= 5.6 mmol/L",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL or >= 5.6 mmol/L",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 9,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5.6,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin =< 1.5 X ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for subjects with total bilirubin levels > 1.5 ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) or prothrombin time (PT) activated partial thromboplastin time (aPTT) =< 1.3 X ULN",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ... =< 1.3 X ULN",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.3,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prothrombin time (PT) ... =< 1.3 X ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.3,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "activated partial thromboplastin time (aPTT) =< 1.3 X ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.3,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability and willingness to comply with the requirements of the study protocol",
            "criterions": [
                {
                    "exact_snippets": "Ability ... to comply with the requirements of the study protocol",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to comply with the requirements of the study protocol",
                    "criterion": "willingness to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All screening labs should be performed within 14 days (+3 working days) of treatment initiation",
            "criterions": [
                {
                    "exact_snippets": "All screening labs should be performed within 14 days (+3 working days) of treatment initiation",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 17,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be at least 12 weeks out from completion of concurrent chemoradiation",
            "criterions": [
                {
                    "exact_snippets": "Patients must be at least 12 weeks out from completion of concurrent chemoradiation",
                    "criterion": "time since completion of concurrent chemoradiation",
                    "requirements": [
                        {
                            "requirement_type": "duration_since_completion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 X upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measured or calculated creatinine clearance ... >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "applicability_condition",
                            "expected_value": "for subject with creatinine levels > 1.5 X institutional ULN"
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl] ... >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "applicability_condition",
                            "expected_value": "for subject with creatinine levels > 1.5 X institutional ULN"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed informed consent form (ICF)",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent form (ICF)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the duration of the study and 5 months after the last dose of study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential should be willing to use 2 methods of birth control",
                    "criterion": "birth control use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "or be surgically sterile",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "or abstain from heterosexual activity for the duration of the study and 5 months after the last dose of study treatment",
                    "criterion": "abstinence from heterosexual activity",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study and 5 months after the last dose of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "surgical sterilization",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "free from menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol) OR 24 hour (h) urine protein =< 1g",
            "criterions": [
                {
                    "exact_snippets": "Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol)",
                    "criterion": "urine protein/creatinine ratio (UPCR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "mg/mg"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 113.2,
                                "unit": "mg/mmol"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "24 hour (h) urine protein =< 1g",
                    "criterion": "24 hour urine protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A baseline brain magnetic resonance imaging (MRI) obtained no more than 14 days prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "A baseline brain magnetic resonance imaging (MRI) obtained no more than 14 days prior to study enrollment",
                    "criterion": "baseline brain MRI",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to study enrollment"
                            }
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000 /mcL",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000 /mcL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/mcL"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Evidence of recent hemorrhage on post-operative MRI of the brain, however patients with clinically asymptomatic presence of hemosiderin, resolving post-operative changes and punctate intratumoral hemorrhage are permitted",
            "criterions": [
                {
                    "exact_snippets": "Evidence of recent hemorrhage on post-operative MRI of the brain",
                    "criterion": "recent hemorrhage on post-operative brain MRI",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically asymptomatic presence of hemosiderin",
                    "criterion": "clinically asymptomatic presence of hemosiderin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "resolving post-operative changes",
                    "criterion": "resolving post-operative changes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "punctate intratumoral hemorrhage",
                    "criterion": "punctate intratumoral hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "prior allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of hypertensive crisis or hypertensive encephalopathy",
            "criterions": [
                {
                    "exact_snippets": "Prior history of hypertensive crisis",
                    "criterion": "hypertensive crisis",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... hypertensive encephalopathy",
                    "criterion": "hypertensive encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has history of interstitial lung disease or active, non-infectious pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "history of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active, non-infectious pneumonitis",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to comply with study and follow-up procedures",
            "criterions": [
                {
                    "exact_snippets": "Inability to comply with study and follow-up procedures",
                    "criterion": "ability to comply with study and follow-up procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled",
                    "criterion": "acute, low-dose, systemic immunosuppressant medication use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "low-dose"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "acute"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
            "criterions": [
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "psychiatric disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "substance abuse disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that would interfere with cooperation with the requirements of the trial",
                    "criterion": "ability to cooperate with trial requirements",
                    "requirements": [
                        {
                            "requirement_type": "interference",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has history of cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation",
            "criterions": [
                {
                    "exact_snippets": "Has history of cavitating pulmonary lesion(s)",
                    "criterion": "cavitating pulmonary lesion(s)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known endotracheal or endobronchial disease manifestation",
                    "criterion": "endotracheal or endobronchial disease manifestation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of intracranial abscess within 6 months prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "History of intracranial abscess within 6 months prior to study enrollment",
                    "criterion": "intracranial abscess",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible",
            "criterions": [
                {
                    "exact_snippets": "controlled type 1 diabetes mellitus",
                    "criterion": "type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable insulin regimen",
                    "criterion": "insulin regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate to severe hepatic impairment (Child-Pugh B or C)",
            "criterions": [
                {
                    "exact_snippets": "Moderate to severe hepatic impairment (Child-Pugh B or C)",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "Child-Pugh classification",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations",
            "criterions": [
                {
                    "exact_snippets": "Patients with psoriasis",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a baseline ophthalmologic exam",
                    "criterion": "baseline ophthalmologic exam",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "to rule out ocular manifestations",
                    "criterion": "ocular manifestations",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Contraindication for undergoing MRIs",
            "criterions": [
                {
                    "exact_snippets": "Contraindication for undergoing MRIs",
                    "criterion": "contraindication for MRI",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has clinically relevant ongoing complications from prior radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "clinically relevant ongoing complications from prior radiation therapy",
                    "criterion": "complications from prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "clinical relevance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ongoing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically-significant disorders that would preclude safe study participation",
            "criterions": [
                {
                    "exact_snippets": "Clinically-significant disorders that would preclude safe study participation",
                    "criterion": "clinically-significant disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude safe study participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
            "criterions": [
                {
                    "exact_snippets": "Any other diseases ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
                    "criterion": "other diseases or conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "metabolic dysfunction ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
                    "criterion": "metabolic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "physical examination finding ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
                    "criterion": "abnormal physical examination finding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical laboratory finding ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
                    "criterion": "abnormal clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction",
            "criterions": [
                {
                    "exact_snippets": "History of tumor invading the GI tract",
                    "criterion": "tumor invasion of the GI tract",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active peptic ulcer disease",
                    "criterion": "peptic ulcer disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease (e.g., Crohn's disease)",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cholecystitis",
                    "criterion": "cholecystitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic cholangitis",
                    "criterion": "cholangitis",
                    "requirements": [
                        {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "appendicitis",
                    "criterion": "appendicitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute pancreatitis",
                    "criterion": "pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute obstruction of the pancreatic duct or common bile duct",
                    "criterion": "obstruction of the pancreatic duct or common bile duct",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastric outlet obstruction",
                    "criterion": "gastric outlet obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 2 weeks prior to cycle 1, day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to swallow tablets",
            "criterions": [
                {
                    "exact_snippets": "Inability to swallow tablets",
                    "criterion": "ability to swallow tablets",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of human immunodeficiency virus (HIV) infection or active hepatitis B (HBV) (chronic or acute) or hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B (HBV) (chronic or acute)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": [
                                "chronic",
                                "acute"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
            "criterions": [
                {
                    "exact_snippets": "use of inhaled corticosteroids ... is allowed",
                    "criterion": "inhaled corticosteroids use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use of ... mineralocorticoids (e.g., fludrocortisone) ... is allowed",
                    "criterion": "mineralocorticoids use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with orthostatic hypotension",
                    "criterion": "orthostatic hypotension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with ... adrenocortical insufficiency",
                    "criterion": "adrenocortical insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known leptomeningeal disease, gliomatosis cerebri, extracranial disease, or multifocal disease. Subject has multifocal glioblastoma (GBM), defined as discrete sites of contrast enhancing disease without contiguous T2/fluid attenuated inversion recovery (FLAIR) abnormality that require distinct radiotherapy ports. Satellite lesions that are associated with a contiguous area of T2/FLAIR abnormality as the main lesion(s) and that are encompassed within the same radiotherapy port as the main lesion(s) are permitted",
            "criterions": [
                {
                    "exact_snippets": "Has known leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gliomatosis cerebri",
                    "criterion": "gliomatosis cerebri",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "extracranial disease",
                    "criterion": "extracranial disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multifocal disease",
                    "criterion": "multifocal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject has multifocal glioblastoma (GBM), defined as discrete sites of contrast enhancing disease without contiguous T2/fluid attenuated inversion recovery (FLAIR) abnormality that require distinct radiotherapy ports",
                    "criterion": "multifocal glioblastoma (GBM) with discrete sites of contrast enhancing disease without contiguous T2/FLAIR abnormality requiring distinct radiotherapy ports",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)",
            "criterions": [
                {
                    "exact_snippets": "Disease is well controlled at baseline",
                    "criterion": "disease control status at baseline",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)",
                    "criterion": "topical steroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "potency",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH) are allowed",
            "criterions": [
                {
                    "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection ... are allowed",
                    "criterion": "prophylactic use of low-dose aspirin for cardio-protection",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "low-dose low molecular weight heparins (LMWH) are allowed",
                    "criterion": "low-dose low molecular weight heparins (LMWH) use",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Rash must cover less than 10% of body surface area (BSA)",
            "criterions": [
                {
                    "exact_snippets": "Rash must cover less than 10% of body surface area (BSA)",
                    "criterion": "rash body surface area coverage",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "% of BSA"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may not receive concomitant chemotherapy, hormonal therapy, immunotherapy, or radiotherapy while patients are on study",
            "criterions": [
                {
                    "exact_snippets": "may not receive concomitant chemotherapy",
                    "criterion": "concomitant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "may not receive concomitant ... hormonal therapy",
                    "criterion": "concomitant hormonal therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "may not receive concomitant ... immunotherapy",
                    "criterion": "concomitant immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "may not receive concomitant ... radiotherapy",
                    "criterion": "concomitant radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1",
                    "criterion": "antibiotic administration",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "oral",
                                "IV"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to cycle 1, day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, fusion proteins or components of cabozantinib",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies",
                    "criterion": "hypersensitivity reactions to chimeric or humanized antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to ... fusion proteins",
                    "criterion": "hypersensitivity reactions to fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to ... components of cabozantinib",
                    "criterion": "hypersensitivity reactions to components of cabozantinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anticipation of need for a major surgical procedure (e.g., laparoscopic nephrectomy, gastrointestinal [GI] surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment, or of need for a minor surgery within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Anticipation of need for a major surgical procedure ... within 2 weeks before first dose of study treatment",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing before first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "need for a minor surgery within 10 days before first dose of study treatment",
                    "criterion": "anticipated need for minor surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing before first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment",
                    "criterion": "wound healing from prior surgery",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with clinically relevant ongoing complications from prior surgery are not eligible",
                    "criterion": "clinically relevant ongoing complications from prior surgery",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study and for 5 months after last dose of atezolizumab",
            "criterions": [
                {
                    "exact_snippets": "Influenza vaccination should be given during influenza season only (approximately October to March)",
                    "criterion": "influenza vaccination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during influenza season only (approximately October to March)"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1",
                    "criterion": "live, attenuated influenza vaccine receipt",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to cycle 1, day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) ... at any time during the study and for 5 months after last dose of atezolizumab",
                    "criterion": "live, attenuated influenza vaccine receipt",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": [
                                "during the study",
                                "for 5 months after last dose of atezolizumab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating in any other recurrent therapeutic trial after completion of chemoradiation",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating in any other recurrent therapeutic trial after completion of chemoradiation",
                    "criterion": "participation in other recurrent therapeutic trial",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after completion of chemoradiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator",
            "criterions": [
                {
                    "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial",
                    "criterion": "condition, therapy, or laboratory abnormality that might confound the results of the trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might ... interfere with the subject's participation for the full duration of the trial",
                    "criterion": "condition, therapy, or laboratory abnormality that might interfere with participation for the full duration of the trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that ... is not in the best interest of the subject to participate, in the opinion of the treating investigator",
                    "criterion": "condition, therapy, or laboratory abnormality that is not in the best interest of the subject to participate, in the opinion of the treating investigator",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
            "criterions": [
                {
                    "exact_snippets": "History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
                    "criterion": "history of radiation pneumonitis in the radiation field (fibrosis)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia",
            "criterions": [
                {
                    "exact_snippets": "Severe infections within 4 weeks prior to cycle 1, day 1",
                    "criterion": "severe infections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... within the projected duration of the trial, starting with the screening visit",
                    "criterion": "intention to conceive (female)",
                    "requirements": [
                        {
                            "requirement_type": "intention during trial",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children within the projected duration of the trial, starting with the screening visit",
                    "criterion": "intention to father children (male)",
                    "requirements": [
                        {
                            "requirement_type": "intention during trial",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Assocation (NYHA) grade II or greater congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Assocation (NYHA) grade II or greater congestive heart failure",
                    "criterion": "congestive heart failure (NYHA grade)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence of ... coagulopathy",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of therapeutic anticoagulation",
                    "criterion": "therapeutic anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Has an active infection requiring systemic therapy",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocardial infarction or unstable angina within 6 months prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... within 6 months prior to study enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina within 6 months prior to study enrollment",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or any other history of significant bleeding (e.g. pulmonary hemorrhage) within 12 weeks before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "History of clinically significant hematuria",
                    "criterion": "hematuria",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of clinically significant ... hematemesis",
                    "criterion": "hematemesis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of clinically significant ... hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "amount of red blood",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "ml"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other history of significant bleeding (e.g. pulmonary hemorrhage) within 12 weeks before first dose of study treatment",
                    "criterion": "significant bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 12 weeks before first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel wafers will be excluded. Active treatment with the Optune device will be excluded",
            "criterions": [
                {
                    "exact_snippets": "Has received prior interstitial brachytherapy",
                    "criterion": "prior interstitial brachytherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "implanted chemotherapy",
                    "criterion": "prior implanted chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "therapeutics delivered by local injection or convection enhanced delivery",
                    "criterion": "prior therapeutics delivered by local injection or convection enhanced delivery",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with Gliadel wafers will be excluded",
                    "criterion": "prior treatment with Gliadel wafers",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active treatment with the Optune device will be excluded",
                    "criterion": "active treatment with the Optune device",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0)",
            "criterions": [
                {
                    "exact_snippets": "Malignancies other than the disease under study within 5 years prior to cycle 1, day 1",
                    "criterion": "history of other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent)",
                    "criterion": "history of specific low-risk malignancies",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "expected outcome",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "adequately treated carcinoma in situ of the cervix",
                                "basal cell skin cancer",
                                "squamous cell skin cancer",
                                "ductal carcinoma in situ treated surgically with curative intent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0)",
                    "criterion": "malignancy under active surveillance",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "active surveillance"
                        },
                        {
                            "requirement_type": "standard-of-care",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "chronic lymphocytic leukemia Rai Stage 0"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* MEDICATION-RELATED EXCLUSION CRITERIA:",
            "criterions": [
                {
                    "exact_snippets": "MEDICATION-RELATED EXCLUSION CRITERIA",
                    "criterion": "medication use",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncompensated/symptomatic hypothyroidism",
            "criterions": [
                {
                    "exact_snippets": "Uncompensated/symptomatic hypothyroidism",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "compensation status",
                            "expected_value": "uncompensated"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before cycle 1, day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live, attenuated vaccine will be required during the study",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated requirement during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "complete healing"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "before first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known lesions invading or encasing any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible",
            "criterions": [
                {
                    "exact_snippets": "Known lesions invading or encasing any major blood vessels",
                    "criterion": "lesions invading or encasing major blood vessels",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible",
                    "criterion": "lesions invading intrahepatic vasculature (portal vein, hepatic vein, hepatic artery)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a medical history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Has a medical history of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a medical history of ... pneumonitis (including drug induced)",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a medical history of ... organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a medical history of ... bronchiolitis obliterans",
                    "criterion": "bronchiolitis obliterans",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a medical history of ... cryptogenic organizing pneumonia",
                    "criterion": "cryptogenic organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious medical condition that interferes with adherence to study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any serious medical condition that interferes with adherence to study procedures",
                    "criterion": "serious medical condition",
                    "requirements": [
                        {
                            "requirement_type": "interference with adherence to study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible",
            "criterions": [
                {
                    "exact_snippets": "history of autoimmune hypothyroidism",
                    "criterion": "autoimmune hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose of thyroid replacement hormone",
                    "criterion": "thyroid replacement hormone",
                    "requirements": [
                        {
                            "requirement_type": "stable dose",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: if a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 minutes after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility",
            "criterions": [
                {
                    "exact_snippets": "a single ECG shows a QTcF with an absolute value > 500 ms ... the average of these three consecutive results for QTcF will be used to determine eligibility",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "average value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrollment",
                    "criterion": "significant vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic aneurysm requiring surgical repair",
                    "criterion": "aortic aneurysm requiring surgical repair",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "recent peripheral arterial thrombosis",
                    "criterion": "peripheral arterial thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment",
                    "criterion": "systemic anticancer therapy receipt",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose of study treatment"
                            }
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "cytotoxic",
                                "biologic",
                                "other systemic anticancer therapy",
                                "investigational"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible. Patients will be sampled for HBV DNA and will be referred to a virologist to monitor for HBV re-activation",
            "criterions": [
                {
                    "exact_snippets": "negative hepatitis B surface antigen [HBsAg] test",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive anti-HBc [antibody to hepatitis B core antigen] antibody test",
                    "criterion": "anti-HBc antibody (antibody to hepatitis B core antigen)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "sampled for HBV DNA",
                    "criterion": "HBV DNA",
                    "requirements": [
                        {
                            "requirement_type": "sampling",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "monitor for HBV re-activation",
                    "criterion": "HBV re-activation",
                    "requirements": [
                        {
                            "requirement_type": "monitoring",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with anti-PD-1",
                    "criterion": "prior treatment with anti-PD-1 therapeutic antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... anti-PD-L1 therapeutic antibody",
                    "criterion": "prior treatment with anti-PD-L1 therapeutic antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... pathway-targeting agents",
                    "criterion": "prior treatment with pathway-targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment",
                    "criterion": "small molecule kinase inhibitor receipt",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)",
            "criterions": [
                {
                    "exact_snippets": "No acute exacerbations of underlying condition within the last 12 months",
                    "criterion": "acute exacerbations of underlying condition",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "in the last 12 months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids",
                    "criterion": "treatment for underlying condition",
                    "requirements": [
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment_types",
                            "expected_value": [
                                "psoralen plus ultraviolet A radiation (PUVA)",
                                "methotrexate",
                                "retinoids",
                                "biologic agents",
                                "oral calcineurin inhibitors",
                                "high potency steroids",
                                "oral steroids"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible",
                    "criterion": "prophylactic antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequately controlled hypertension (defined as systolic blood pressure > 140mmHg and/or diastolic blood pressure > 90mmHg)",
            "criterions": [
                {
                    "exact_snippets": "Inadequately controlled hypertension (defined as systolic blood pressure > 140mmHg and/or diastolic blood pressure > 90mmHg)",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Inadequately controlled hypertension (defined as systolic blood pressure > 140mmHg and/or diastolic blood pressure > 90mmHg)",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Core biopsy (excluding intracranial biopsy) or other minor surgical procedure within 107 days prior to study enrollment. Placement of a central vascular access device if performed within 2 days prior to cabozantinib administration",
            "criterions": [
                {
                    "exact_snippets": "Core biopsy (excluding intracranial biopsy) or other minor surgical procedure within 107 days prior to study enrollment",
                    "criterion": "core biopsy or other minor surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 107,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "procedure location",
                            "expected_value": "excluding intracranial"
                        }
                    ]
                },
                {
                    "exact_snippets": "Placement of a central vascular access device if performed within 2 days prior to cabozantinib administration",
                    "criterion": "placement of a central vascular access device",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relation to drug administration",
                            "expected_value": "prior to cabozantinib administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious non-healing wound, active ulcer or untreated bone fracture",
            "criterions": [
                {
                    "exact_snippets": "Serious non-healing wound",
                    "criterion": "non-healing wound",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "active ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1",
                    "criterion": "treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to cycle 1, day 1"
                            }
                        },
                        {
                            "requirement_type": "medication_type",
                            "expected_value": [
                                "prednisone",
                                "cyclophosphamide",
                                "azathioprine",
                                "methotrexate",
                                "thalidomide",
                                "anti-tumor necrosis factor (anti-TNF) agents"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                    "criterion": "QTcF (corrected QT interval by Fridericia formula)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "electrocardiogram (ECG)"
                        },
                        {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 14 days before first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure, open biopsy, intracranial biopsy, ventriculoperitoneal shunt or significant traumatic injury within 28 days prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure ... within 28 days prior to study enrollment",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "open biopsy ... within 28 days prior to study enrollment",
                    "criterion": "open biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "intracranial biopsy ... within 28 days prior to study enrollment",
                    "criterion": "intracranial biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ventriculoperitoneal shunt ... within 28 days prior to study enrollment",
                    "criterion": "ventriculoperitoneal shunt placement",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury within 28 days prior to study enrollment",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since injury",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A history of or active nephrotic syndrome",
            "criterions": [
                {
                    "exact_snippets": "A history of ... nephrotic syndrome",
                    "criterion": "nephrotic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active nephrotic syndrome",
                    "criterion": "nephrotic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of stroke or transient ischemic attack (TIA) within 6 months prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 6 months prior to study enrollment",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... transient ischemic attack (TIA) within 6 months prior to study enrollment",
                    "criterion": "transient ischemic attack (TIA)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor are also allowed",
            "criterions": [
                {
                    "exact_snippets": "Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban",
                    "criterion": "anticoagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "LMWH",
                                "rivaroxaban",
                                "edoxaban",
                                "apixaban"
                            ]
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "therapeutic"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects without known brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment",
                    "criterion": "anticoagulant dose stability",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor",
                    "criterion": "clinically significant hemorrhagic complications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:",
            "criterions": [
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded)",
                    "criterion": "skin conditions (eczema, psoriasis, lichen simplex chronicus, vitiligo)",
                    "requirements": [
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g. , dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel)",
            "criterions": [
                {
                    "exact_snippets": "Concomitant anticoagulation with coumarin agents (e.g., warfarin)",
                    "criterion": "concomitant anticoagulation with coumarin agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... direct thrombin inhibitors (e.g. , dabigatran)",
                    "criterion": "concomitant anticoagulation with direct thrombin inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... direct factor Xa inhibitor betrixaban",
                    "criterion": "concomitant anticoagulation with direct factor Xa inhibitor betrixaban",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... platelet inhibitors (e.g., clopidogrel)",
                    "criterion": "concomitant anticoagulation with platelet inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of abdominal fistula, bowel obstruction, gastrointestinal perforation or intra-abdominal abscess within 6 months before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal fistula ... within 6 months before first dose of study treatment",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... bowel obstruction ... within 6 months before first dose of study treatment",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... gastrointestinal perforation ... within 6 months before first dose of study treatment",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intra-abdominal abscess within 6 months before first dose of study treatment",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with anti-angiogenic (e.g. anti-vascular endothelial growth factor [VEGF]) therapeutic antibody or pathway targeting agents",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with anti-angiogenic (e.g. anti-vascular endothelial growth factor [VEGF]) therapeutic antibody or pathway targeting agents",
                    "criterion": "prior treatment with anti-angiogenic therapeutic antibody or pathway targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]- or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]- or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1",
                    "criterion": "treatment with systemic immunostimulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis",
            "criterions": [
                {
                    "exact_snippets": "History or risk of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus",
                    "criterion": "systemic lupus erythematosus",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vascular thrombosis associated with antiphospholipid syndrome",
                    "criterion": "vascular thrombosis associated with antiphospholipid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wegener's granulomatosis",
                    "criterion": "Wegener's granulomatosis",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Sjogren's syndrome",
                    "criterion": "Sjogren's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Bell's palsy",
                    "criterion": "Bell's palsy",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Guillain-Barre syndrome",
                    "criterion": "Guillain-Barre syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple sclerosis",
                    "criterion": "multiple sclerosis",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune thyroid disease",
                    "criterion": "autoimmune thyroid disease",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vasculitis",
                    "criterion": "vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerulonephritis",
                    "criterion": "glomerulonephritis",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA",
            "criterions": [
                {
                    "exact_snippets": "Patients positive for hepatitis C virus (HCV) antibody",
                    "criterion": "hepatitis C virus (HCV) antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "PCR is negative for HCV RNA",
                    "criterion": "HCV RNA by PCR",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment, or systemic treatment with radionuclides within 6 weeks before first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Has received radiation therapy for bone metastasis within 2 weeks before first dose of study treatment",
                    "criterion": "radiation therapy for bone metastasis",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                    "criterion": "other radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic treatment with radionuclides within 6 weeks before first dose of study treatment",
                    "criterion": "systemic treatment with radionuclides",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}